BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 31047049)

  • 1. Biotin and arginine modified hydroxypropyl-β-cyclodextrin nanoparticles as novel drug delivery systems for paclitaxel.
    Yan C; Liang N; Li Q; Yan P; Sun S
    Carbohydr Polym; 2019 Jul; 216():129-139. PubMed ID: 31047049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of a 2-HP-β-Cyclodextrin Formulation on the Biological Transport and Delivery of Chemotherapeutic PLGA Nanoparticles.
    Zheng K; Huang Z; Huang J; Liu X; Ban J; Huang X; Luo H; Chen Z; Xie Q; Chen Y; Lu Z
    Drug Des Devel Ther; 2021; 15():2605-2618. PubMed ID: 34168432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modification of paclitaxel-loaded solid lipid nanoparticles with 2-hydroxypropyl-β-cyclodextrin enhances absorption and reduces nephrotoxicity associated with intravenous injection.
    Baek JS; Kim JH; Park JS; Cho CW
    Int J Nanomedicine; 2015; 10():5397-405. PubMed ID: 26347363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipoprotein-Inspired Nanocarrier Composed of Folic Acid-Modified Protein and Lipids: Preparation and Evaluation of Tumor-Targeting Effect.
    Han M; Ji X; Li J; Ge Z; Luo B; Zhou K; Wang Q; Sun X; Zhang W; Li J
    Int J Nanomedicine; 2020; 15():3433-3445. PubMed ID: 32523342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2-Hydroxypropyl-β-cyclodextrin-modified SLN of paclitaxel for overcoming p-glycoprotein function in multidrug-resistant breast cancer cells.
    Baek JS; Cho CW
    J Pharm Pharmacol; 2013 Jan; 65(1):72-8. PubMed ID: 23215690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulating Tumor-Associated Macrophage Polarization by Cyclodextrin-Modified PLGA Nanoparticles Loaded with R848 for Treating Colon Cancer.
    Yuan H; Gui H; Chen S; Zhu L; Wang C; Jing Q; Lv H; Wan Q; Wang S; Zhou S; Ren X; Nie Y; Li L
    Int J Nanomedicine; 2024; 19():3589-3605. PubMed ID: 38645464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Free paclitaxel loaded PEGylated-paclitaxel nanoparticles: preparation and comparison with other paclitaxel systems in vitro and in vivo.
    Lu J; Chuan X; Zhang H; Dai W; Wang X; Wang X; Zhang Q
    Int J Pharm; 2014 Aug; 471(1-2):525-35. PubMed ID: 24858391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hydroxypropyl-β-cyclodextrin-graphene oxide conjugates: Carriers for anti-cancer drugs.
    Tan J; Meng N; Fan Y; Su Y; Zhang M; Xiao Y; Zhou N
    Mater Sci Eng C Mater Biol Appl; 2016 Apr; 61():681-7. PubMed ID: 26838897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inclusion complex based on N-acetyl-L-cysteine and arginine modified hydroxypropyl-β-cyclodextrin for oral insulin delivery.
    Li S; Liang N; Yan P; Kawashima Y; Sun S
    Carbohydr Polym; 2021 Jan; 252():117202. PubMed ID: 33183638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-weight polyethylenimine cross-linked 2-hydroxypopyl-β-cyclodextrin and folic acid as an efficient and nontoxic siRNA carrier for gene silencing and tumor inhibition by VEGF siRNA.
    Li JM; Wang YY; Zhang W; Su H; Ji LN; Mao ZW
    Int J Nanomedicine; 2013; 8():2101-17. PubMed ID: 23766646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paclitaxel/hydroxypropyl-β-cyclodextrin complex-loaded liposomes for overcoming multidrug resistance in cancer chemotherapy.
    Shen Q; Shen Y; Jin F; Du YZ; Ying XY
    J Liposome Res; 2020 Mar; 30(1):12-20. PubMed ID: 30741058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterisation of 2-HP-β-cyclodextrin-PLGA nanoparticle complexes for potential use as ocular drug delivery vehicles.
    Li F; Wen Y; Zhang Y; Zheng K; Ban J; Xie Q; Wen Y; Liu Q; Chen F; Mo Z; Liu L; Chen Y; Lu Z
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):4097-4108. PubMed ID: 31663388
    [No Abstract]   [Full Text] [Related]  

  • 13. Novel free-paclitaxel-loaded redox-responsive nanoparticles based on a disulfide-linked poly(ethylene glycol)-drug conjugate for intracellular drug delivery: synthesis, characterization, and antitumor activity in vitro and in vivo.
    Chuan X; Song Q; Lin J; Chen X; Zhang H; Dai W; He B; Wang X; Zhang Q
    Mol Pharm; 2014 Oct; 11(10):3656-70. PubMed ID: 25208098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanoformulation of Paclitaxel: Exploring the Cyclodextrin / PLGA Nano Delivery Carrier to Slow Down Paclitaxel Release, Enhance Accumulation
    Ma P; Huang J; Liu J; Zhu Y; Chen J; Chen J; Lei L; Guan Z; Ban J; Lu Z
    J Cancer; 2023; 14(5):759-769. PubMed ID: 37056390
    [No Abstract]   [Full Text] [Related]  

  • 15. Hyaluronic acid decorated pluronic P85 solid lipid nanoparticles as a potential carrier to overcome multidrug resistance in cervical and breast cancer.
    Wang F; Li L; Liu B; Chen Z; Li C
    Biomed Pharmacother; 2017 Feb; 86():595-604. PubMed ID: 28027535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor Targeting and pH-Sensitive Inclusion Complex Based on HP-β-CD as a Potential Carrier for Paclitaxel: Fabrication, Molecular Docking, and Characterization.
    Li Z; Zhao W; Liang N; Yan P; Sun S
    Biomacromolecules; 2023 Jan; 24(1):178-189. PubMed ID: 36538015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted Nanostructured Lipid Carriers for Delivery of Paclitaxel to Cancer Cells: Preparation, Characterization, and Cell Toxicity.
    Rezazadeh M; Emami J; Hassanzadeh F; Sadeghi H; Rostami M; Mohammadkhani H
    Curr Drug Deliv; 2017; 14(8):1189-1200. PubMed ID: 28472908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyaluronic acid-modified selenium nanoparticles for enhancing the therapeutic efficacy of paclitaxel in lung cancer therapy.
    Zou J; Su S; Chen Z; Liang F; Zeng Y; Cen W; Zhang X; Xia Y; Huang D
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):3456-3464. PubMed ID: 31469318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced antitumor efficacy by d-glucosamine-functionalized and paclitaxel-loaded poly(ethylene glycol)-co-poly(trimethylene carbonate) polymer nanoparticles.
    Jiang X; Xin H; Gu J; Du F; Feng C; Xie Y; Fang X
    J Pharm Sci; 2014 May; 103(5):1487-96. PubMed ID: 24619482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-binding albumins forming stabilized nanoparticles for co-delivery of paclitaxel and resveratrol: In vitro/in vivo evaluation and binding properties investigation.
    Zhao Y; Cai C; Liu M; Zhao Y; Wu Y; Fan Z; Ding Z; Zhang H; Wang Z; Han J
    Int J Biol Macromol; 2020 Jun; 153():873-882. PubMed ID: 32169451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.